Valeo Pharma (TSX:VPH) ROCE % : -252.74% (As of Jan. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Valeo Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Valeo Pharma's annualized ROCE % for the quarter that ended in Jan. 2024 was -252.74%.

Valeo Pharma ROCE % Historical Data

The historical data trend for Valeo Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valeo Pharma ROCE % Chart

Valeo Pharma Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

ROCE %

Get a 7-Day Free Trial

-421.27

-103.88

-208.01

-84.16

-43.90

Valeo Pharma Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
ROCE %	Get a 7-Day Free Trial															-29.81	-35.21	-30.25	-87.59	-252.74

Valeo Pharma ROCE % Calculation

Valeo Pharma's annualized ROCE % for the fiscal year that ended in Oct. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Oct. 2023 )		(A: Oct. 2022 )		(A: Oct. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Oct. 2023 )		(A: Oct. 2022 )		(A: Oct. 2023 )
	=	-14.018	/	( ( (58.265 - 15.339)	+	(41.207 - 20.274) )	/ 2 )
	=	-14.018	/	( (42.926	+	20.933)	/ 2 )
	=	-14.018	/	31.9295
	=	-43.90 %

Valeo Pharma's ROCE % of for the quarter that ended in Jan. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	-12.264	/	( ( (41.207 - 20.274)	+	(40.353 - 51.581) )	/ 2 )
	=	-12.264	/	( ( 20.933	+	-11.228 )	/ 2 )
	=	-12.264	/	4.8525
	=	-252.74 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

Valeo Pharma (TSX:VPH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Valeo Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of Valeo Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Valeo Pharma (TSX:VPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Valeo Pharma Inc (TSX:VPH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

VPHIF:USA

Address

16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9

Website

https://www.valeopharma.com

Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and Niche hospital injectable products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.

Executives

Luc Mainville

Senior Officer

Valeo Pharma (TSX:VPH) Headlines

No Headlines